Levetiracetam
Product Images NDC 62332-626

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 62332-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 2 (Levetiracetam 03)

Figure 2 (Levetiracetam 03)
This appears to be a portion of a chart showing the percentage of patients in a study who received a placebo or varying dosages of a medication called Levetiracetam. The top row appears to be cut off, so it is not clear what is being measured.*
FDA Label Image

Figure 3 (Levetiracetam 04)

Figure 3 (Levetiracetam 04)
The text provides percentages of patients and two treatment groups, placebo (N=104) and levetiracetam 3000 mg/day (N=180). However, there is no available context to determine the specifics of the study, such as the condition being treated or the methodology.*
FDA Label Image

Figure 4 (Levetiracetam 05)

Figure 4 (Levetiracetam 05)
This appears to be a table or a graph showing percentages of patients taking placebo and levetiracetam for an unknown medical condition. The percentage values are 44.6% and 19.6%, and there are also percentages of 15% and unknown values. The data is divided into two groups, "Placebo" and "Levetiracetam," each with a sample size of 97 and 101 patients respectively.*
FDA Label Image

Figure 6 (Levetiracetam 06)

Figure 6 (Levetiracetam 06)
This is a chart that compares the efficacy of placebo versus Levetiracetam among patients. The chart shows the percentage of patients on the y-axis from 0% to 100%, with intervals of 10%. The x-axis has no labels but shows two groups: Placebo (N=84) and Levetiracetam (N=79). The data points show that 45.2% of patients in the Levetiracetam group had positive outcomes compared to the placebo group, which had a 0% outcome. However, there is an error as the percentage value for the Levetiracetam group is shown as 722%, which is not available.*
FDA Label Image

100 mg/ml (Levetiracetam 100mgperml)

100 mg/ml (Levetiracetam 100mgperml)
Levetiracetam is an oral solution used to treat seizures in adults and children. Each mL of the solution contains 100 mg of leviracetam USP. The recommended dosage should be checked from the package insert. The medicine should be stored at a temperature between 20°-25°C. It should be kept in light-resistant packaging with a child-resistant closure. Levetiracetam is manufactured by the Lannett Company, Inc., and marketed by Alembic Pharmaceuticals, Inc. Upon dispensing, each patient should receive the accompanying medication guide. The NDC (national drug code) for Levetiracetam Oral Solution is 62332-626-16. A warning is issued to keep this medicine away from children. However, the text mentions some corrupted characters which might depreciate its readability.*
FDA Label Image

Figure 1 (Levetiracetam Fig1)

Figure 1 (Levetiracetam Fig1)
This is a table showing the percentage of patients in a clinical trial receiving a placebo and two different doses (1000mg/day and 3000mg/day) of a medication called Levetiracetam. The total number of patients for each group (Placebo, Levetiracetam 1000mg/day, and Levetiracetam 3000mg/day) are also provided.*
FDA Label Image

Structure (Levetiracetam Structure)

Structure (Levetiracetam Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.